IP Library Granted Patent US 10,738,286
Granted Patent B2
US 10,738,286 · App. 16/012,462 · Granted Aug 11, 2020

T7 RNA polymerase variants

Inventors: Mathew G. Miller (San Carlos, CA); Chinping Chng (Menlo Park, CA); Oscar Alvizo (Fremont, CA); Melissa Ann Mayo (Foster City, CA); James Nicholas Riggins (San Francisco, CA); Xiang Yi (Foster City, CA); Jonathan S. Penfield (Truckee, CA); Gjalt W. Huisman (Redwood City, CA); Jared Davis (Cheshire, CT); Yasushi Saotome (Solana Beach, CA)
Assignee: Codexis, Inc.
C12N9/1247C12N15/00C12P19/34C12Y207/07006
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,738,286
App. No.
16/012,462
Granted
Aug 11, 2020
Kind
B2
Abstract

The present invention provides engineered RNA polymerase variants and compositions comprising these variants. The present invention further provides engineered T7 RNA polymerase variants and compositions comprising these variants. These variants have been evolved for selective incorporation of the m7G(5′)ppp(5′)m7G cap analog over GTP at the initiation of in vitro transcription. The present invention also provides methods for selective capping of RNA transcripts.

Claims (22)

1. An engineered RNA polymerase, wherein said polymerase utilizes a cap or cap analog during transcription initiation, and wherein said engineered RNA polymerase comprises a polypeptide sequence having at least 95% sequence identity to SEQ ID NO: 4 and further comprises a mutation at position 664, wherein said position is numbered with reference to SEQ ID NO: 4.

2. The engineered RNA polymerase of claim 1 , wherein said RNA polymerase preferentially utilizes a cap or cap analog during transcription initiation.

3. The engineered RNA polymerase of claim 1 , wherein said RNA polymerase does not utilize a cap or cap analog during transcription elongation.

4. The engineered RNA polymerase of claim 1 , wherein said engineered RNA polymerase is an engineered T7 RNA polymerase.

5. The engineered RNA polymerase of claim 1 , wherein said polypeptide sequence further comprises a substitution set selected from 513/660/664, 513/635/664, 513/660/664, and 660/664, and/or any combinations thereof, wherein the amino acid positions are numbered with reference to SEQ ID NO: 4.

6. The engineered RNA polymerase of claim 1 , wherein said polypeptide sequence further comprises at least one substitution or substitution set selected from 397, 397/513, 397/513/635, 397/513/635/656, 397/513/635/656/660, 397/513/635/656, 397/513/635/660, 397/513/635, 397/513/656/660, 397/513/660, 397/635, 397/635/656/660, 397/635/656, 397/635/660, 397/635, 397/6351850, 397/660, and/or any combinations thereof, wherein the amino acid positions are numbered with reference to SEQ ID NO: 4.

7. The engineered RNA polymerase of claim 1 , wherein said engineered polymerase exhibits at least one improved property compared to wild-type T7 RNA polymerase.

8. The engineered RNA polymerase of claim 7 , wherein said at least one improved property comprises improved selectivity for cap analog relative to GTP during transcription initiation.

9. The engineered RNA polymerase of claim 1 , wherein the polymerase maintains RNA yield, transcription fidelity, thermostability, protein expression, stability at −20° C., or stability in reaction conditions equivalent to the wild-type T7 RNA polymerase.

10. The engineered RNA polymerase of claim 1 , wherein said RNA polymerase generates greater than about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more capped RNA transcripts relative to uncapped transcripts.

11. The engineered RNA polymerase of claim 10 , wherein said RNA polymerase generates greater than 90% capped RNA transcripts relative to uncapped transcripts.

12. The engineered RNA polymerase of claim 1 , wherein said engineered polymerase is purified.

13. A composition comprising at least one engineered RNA polymerase of claim 1 .

14. A method for producing capped RNA transcripts, comprising providing a composition comprising: i) at least one engineered RNA polymerase of claim 1 , a dinucleotide cap analog, and ii) a DNA template; exposing said DNA template to said composition under conditions such that said engineered RNA polymerase produces a capped RNA transcript.

15. The method of claim 14 , where the dinucleotide cap analog is alpha, gamma-bis(N7-methylguanosine) triphosphate (m7G(5′)ppp(5′)m7G) or an anti-reverse cap analog 3′-O-Me-m 7 G(5′)ppp(5′)G.

16. The method of claim 14 , wherein the dinucleotide cap analog is alpha, gamma-bis(N7-methylguanosine) triphosphate.

17. The method of claim 14 , wherein said engineered RNA polymerase generates greater than about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more capped RNA transcripts relative to uncapped transcripts.

18. The method of claim 17 , wherein said engineered RNA polymerase generates greater than 90% or more capped RNA transcripts relative to uncapped transcripts.

19. The method of claim 18 , wherein said engineered RNA polymerase generates greater than 95% or more capped RNA transcripts relative to uncapped transcripts.

20. The method of claim 14 , wherein said method comprises an in vitro transcription reaction.

21. The engineered RNA polymerase of claim 1 , wherein said polypeptide sequence further comprises at least one substitution or substitution set selected from 513, 513/635, 513/635/656, 513/635/660, 513/656, 513/660, 635, 635/656, 656/660, and 660, wherein the amino acid positions are numbered with reference to SEQ ID NO: 4.

22. The engineered RNA polymerase of claim 9 , wherein said at least one improved property further comprises at least one additional property selected from improved protein expression, improved stability in storage buffer, and improved stability under reaction conditions.

Assignments (4)
SECURITY INTEREST Recorded Feb 15, 2024
From: CODEXIS, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
Reel/Frame 066600/0650 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2019
From: ALEXION PHARMACEUTICALS, INC.
To: CODEXIS, INC.
Reel/Frame 048279/0395 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 7, 2019
From: DAVIS, JARED; SAOTOME, YASUSHI
To: ALEXION PHARMACEUTICALS, INC.
Reel/Frame 048266/0329 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2018
From: MILLER, MATHEW G.; CHNG, CHINPING; ALVIZO, OSCAR; MAYO, MELISSA ANN; RIGGINS, JAMES NICHOLAS; YI, XIANG; PENFIELD, JONATHAN S.; HUISMAN, GJALT W.
To: CODEXIS, INC.
Reel/Frame 046584/0724 →
Continuity (3)
Provisional Application 62527740 · Jun 30, 2017
Provisional Application 62528840 · Jul 5, 2017
Related Publication 20190002850A1 · Jan 3, 2019
Cited By (1)
US 12,680,091